Namenda, Ebixa(memantine)
Axura, Ebixa, Namenda, Namzaric (memantine) is a small molecule pharmaceutical. Memantine was first approved as Ebixa on 2002-05-15. It is used to treat alzheimer disease in the USA. It has been approved in Europe to treat alzheimer disease. It is known to target glutamate receptor ionotropic, NMDA 2C.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Namenda (generic drugs available since 2010-04-14)
CombinationsNamzaric
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Donepezil hydrochloride
+
Memantine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NAMZARIC | AbbVie | N-206439 RX | 2014-12-23 | 4 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| memantine hydrochloride | ANDA | 2023-06-13 |
| namenda | New Drug Application | 2018-11-15 |
| namzaric | New Drug Application | 2019-01-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alzheimer disease | EFO_0000249 | D000544 | F03 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Donepezil Hydrochloride / Memantine Hydrochloride, Namzaric, Abbvie | |||
| 8058291 | 2029-12-05 | U-1641 | |
| 8039009 | 2029-03-24 | U-539, U-1641 | |
| 8168209 | 2025-11-22 | DP | |
| 8173708 | 2025-11-22 | U-1641 | |
| 8283379 | 2025-11-22 | U-1641 | |
| 8293794 | 2025-11-22 | DP | |
| 8329752 | 2025-11-22 | DP | |
| 8338485 | 2025-11-22 | DP | |
| 8338486 | 2025-11-22 | U-1641 | |
| 8362085 | 2025-11-22 | U-1641 | |
| 8580858 | 2025-11-22 | U-1641 | |
| 8598233 | 2025-11-22 | DP | |
HCPCS
No data
Clinical
Clinical Trials
212 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 3 | 5 | 9 | 22 | 2 | 40 |
| Dementia | D003704 | F03 | — | 2 | 2 | 5 | 3 | 12 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 4 | 4 | 2 | 1 | 10 |
| Healthy volunteers/patients | — | 7 | 1 | — | 2 | — | 10 | ||
| Autism spectrum disorder | D000067877 | F84.0 | 1 | 4 | 2 | 1 | 1 | 9 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | 4 | 2 | 8 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 4 | 3 | 2 | — | 7 |
| Cognitive dysfunction | D060825 | G31.84 | — | 4 | 3 | 1 | 1 | 7 | |
| Depression | D003863 | F33.9 | — | — | 2 | 3 | — | 5 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 3 | 2 | 1 | — | 5 |
Show 21 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | 5 | 1 | — | 1 | 7 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 2 | 3 | — | 1 | 6 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 5 | 2 | — | — | 5 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 1 | 3 | 2 | — | — | 5 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | 1 | — | 2 | 4 |
| Neoplasms | D009369 | C80 | — | — | 4 | — | — | 4 | |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 3 | 2 | — | — | 3 |
| Neuralgia | D009437 | EFO_0009430 | — | 2 | 1 | — | — | 3 | |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 3 | — | — | 3 |
| Lung neoplasms | D008175 | C34.90 | — | 1 | 2 | — | — | 3 |
Show 19 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asperger syndrome | D020817 | EFO_0003757 | F84.5 | — | 3 | — | — | 1 | 4 |
| Glioblastoma | D005909 | EFO_0000515 | 2 | 2 | — | — | — | 3 | |
| Tobacco use disorder | D014029 | F17 | 2 | 1 | — | — | — | 3 | |
| Dyslexia | D004410 | EFO_0005424 | F81.0 | — | 3 | — | — | — | 3 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | — | — | 1 | 2 |
| Alcohol drinking | D000428 | EFO_0004329 | — | 2 | — | — | — | 2 | |
| Tachycardia | D013610 | HP_0001649 | R00.0 | 1 | 1 | — | — | — | 1 |
| Orthostatic intolerance | D054971 | 1 | 1 | — | — | — | 1 | ||
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | 1 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | — | — | 2 | 3 |
| Gliosarcoma | D018316 | 1 | — | — | — | — | 1 | ||
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | 1 | — | — | — | — | 1 | ||
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 | ||
| Subdural hematoma chronic | D020200 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | — | — | 1 | 1 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | — | — | — | 1 | 1 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | — | — | — | — | 1 | 1 |
| Bulimia nervosa | D052018 | EFO_0005204 | F50.2 | — | — | — | — | 1 | 1 |
| Body dysmorphic disorders | D057215 | F45.22 | — | — | — | — | 1 | 1 | |
| Learning disabilities | D007859 | F81.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MEMANTINE |
| INN | memantine |
| Description | Memantine is a primary aliphatic amine that is the 3,5-dimethyl derivative of 1-aminoadamantane. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. It has a role as a dopaminergic agent, an antiparkinson drug, a NMDA receptor antagonist, a neuroprotective agent and an antidepressant. It is a member of adamantanes and a primary aliphatic amine. It is a conjugate base of a memantinium(1+). It derives from a hydride of an adamantane. |
| Classification | Small molecule |
| Drug class | antivirals/antiparkinsonians (adamantane derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC12CC3CC(C)(C1)CC(N)(C3)C2 |
Identifiers
| PDB | — |
| CAS-ID | 19982-08-2 |
| RxCUI | 6719 |
| ChEMBL ID | CHEMBL807 |
| ChEBI ID | 64312 |
| PubChem CID | 4054 |
| DrugBank | DB01043 |
| UNII ID | W8O17SJF3T (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GRIN2C
GRIN2C
Organism
Homo sapiens
Gene name
GRIN2C
Gene synonyms
NMDAR2C
NCBI Gene ID
Protein name
glutamate receptor ionotropic, NMDA 2C
Protein synonyms
GluN2C(alt_5'UTR_77nt), GluN2C(alt_5'UTR_87nt), GluN2C(del_e2), GluN2C-b alternative isoform, Glutamate [NMDA] receptor subunit epsilon-3, glutamate receptor, ionotropic, N-methyl D-aspartate 2C, N-methyl D-aspartate receptor subtype 2C, N-methyl-D-aspartate receptor subunit 2C, NMDAR2C, NR2C, putative NMDtranscript(altAcc_e11), putative NMDtranscript(altDon_e4), putative NMDtranscript(del_e4)
Uniprot ID
Mouse ortholog
Grin2c (14813)
glutamate receptor ionotropic, NMDA 2C (Q01098)
Variants
Clinical Variant
No data
Financial
Namenda - Allergan
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Namenda - Warner Chilcott
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Namzaric - Allergan
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Namzaric - Warner Chilcott
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,468 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,374 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more